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ABSTRACT
In this case report of a patient with angioimmunoblastic T-cell lymphoma (AITL), we describe the occurrence of three sequen-
tial complications that have been reported uncommonly in this disease subtype. Firstly, the patient developed hypercalcemia
due to elevated 1,25-didydroxyvitamin D. Although hypercalcemia in AITL is not rare (1-2% incidence), this case was unusual
in that the complication developed when disease appeared stable and symptomatically, he was doing well otherwise. Hyper-
calcemia surprisingly resolved a few months later at a time when his disease appeared to be progressing. A year later, the
patient presented with digital ischemia necessitating partial amputation of a finger. Pathological exam revealed granulomatous
vasculitis of small and medium arterioles with infiltrating malignant T lymphocytes. Although skin manifestations are common
in AITL, necrotizing granulomatous vasculitis with accompanying tumor cells leading to severe digital ischemia appears rare.
Subsequently the patient developed profound pancytopenia with bone marrow confirming severe aplastic anemia. To our
knowledge only one other case of aplastic anemia has been reported in a patient with AITL. We discuss the diagnostic and
management considerations involved in this patient care and review similar reported cases.
Keywords: Angioimmunoblastic T-Cell Lymphoma (AITL); Hypercalcemia; 1,25-dihydroxyvitamin D; Granulomatous vasculi-
tis; Digital ischemia; Aplastic anemia. [Am J Med Sci 2020;&(&):1–8.]
INTRODUCTION
Angioimmunoblastic T-cell lymphoma (AITL)accounts for approximately 15-20% of all periph-eral T-cell lymphomas (PTL) and 1-2% of all non-
Hodgkin’s lymphomas.1 Most patients present with
advanced stage and systemic symptoms yet non-bulky
adenopathy. No treatment standard has been clearly
established and prognosis is relatively poor.2,3 Addition-
ally, patients with AITL may present with a variety of clini-
cal and laboratory characteristics less frequently
encountered in other lymphoma subtypes. Included, for
example, are immunological disturbances involving the
formation of autoantibodies and immune complexes.2−6
Consequently, patients with AITL have been the subject
of a relatively large number of publications detailing a
variety of unusual clinical presentations of this disease.
At the same time, complications such as hypercalcemia
and aplastic anemia (AA) have been reported more fre-
quently in other lymphoma subtypes and are distinctly
rare in AITL. In this report, we describe the sequential
development of three uncommon complications of the
disease occurring in a single patient with AITL, under-
scoring the challenges in managing this disease.
CASE PRESENTATION
A 58-year-old Caucasian male was admitted with
weakness, intermittent fever, and new onset profound
anemia (hemoglobin of 4.2 gm/dl). He denied any bleed-
ing and had no prior history of significant medical ill-
nesses, recent surgery, or trauma.
Physical examination revealed widespread non-bulky
lymphadenopathy. Computed tomography (CT) scans
revealed widespread lymphadenopathy in the neck,
mediastinum, retroperitoneum, pelvis, and inguinal
regions with the largest lymph node 2.2 cm in size. The
spleen was enlarged measuring 15 cm with no focal
lesions.
Laboratory studies revealed white blood cell count
(WBC) 5,600/uL with absolute neutrophil 2,400/uL and
small number of myelocytes as well as atypical lympho-
cytes. Platelet count was 192,000/uL. Direct antiglobulin




test (DAT) was positive for both IgG (3+) and complement
(1+). Haptoglobin was low (<31 mg/dL). Reticulocyte
count however was low (<0.4%). Erythrocyte sedimenta-
tion rate (ESR) was 120 mm/hr. SPEP showed polyclonal
gammopathy with no paraprotein by immunofixation.
Antinuclear antibody (ANA) and rheumatoid factor (RF)
were negative. Serological testing for Hepatitis A, B, C
and HIV 1 and 2 antigen and antibodies were negative.
Lymph node biopsy is shown in Figure 1. The archi-
tecture was completely effaced by a diffuse lymphoid
infiltrate with atrophic/depleted follicles and marked vas-
cular and dendritic cell proliferation. There were clusters
of atypical cells with medium-sized nuclei, dispersed
chromatin, and abundant clear cytoplasm in a back-
ground of reactive lymphocytes, histiocytes, occasional
scattered plasma cells, and eosinophils. The neoplastic
cells were positive for CD3, CD4, CD5, CD10, CD30 (par-
tial), CD45, bcl6, CXCL13, ICOS, PD-1 (CD279) and
vimentin. The cells were negative for CD8, CD15, CD20,
MCK, S100. (Figure 1A-D)
Initial bone marrow exam revealed hypercellularity
(70-80%) with malignant polymorphous infiltrate occupy-
ing 20% of the biopsy. Granulocytic and megakaryocytic
hyperplasia was present with relative erythroid hypopla-
sia (3% on 500-cell count) and moderate to severe retic-
ulin fibrosis. Atypical lymphoid aggregates were positive
for CD3 and CD5, negative for ALK, CD20, and focally
positive in aggregates for CD30. T-cell receptor gene
rearrangement was positive for TCR gamma, negative
for TCR beta. Flow cytometry did not detect the aberrant
T-cell process nor a clonal B-cell population. Cytogenet-
ics were normal (46, XY). (Figure 2A, B)
Diagnosis of Stage IV AITL was established. The
patient was treated initially with prednisone 1mg/kg/day
which resulted in marked improvement in constitutional
symptoms and stabilization of his hemoglobin in the
7,8 gm/dL range. He was discharged from the hospital
and outpatient treatment was subsequently initiated uti-
lizing CHOP-Etoposide every three weeks. However, the
patient was only able to complete two cycles of chemo-
therapy due to poor tolerance with recurring culture neg-
ative fevers, profound weakness, anorexia, and weight
loss. Furthermore, response appeared suboptimal with
minimal reduction of adenopathy. At that point it was
elected to discontinue chemotherapy and restart predni-
sone 1 mg/kg/day while considering other treatment
options. Once again steroids resulted in good palliation
of symptoms with improvement in anemia (hemoglobin
levels >12 gm/dL) and stabilization of lymphadenopathy.
The prednisone dose was tapered periodically over
weeks to 20 mg/day.
Four months after initial presentation he was noted to
have new onset of elevated serum calcium level of
13.4 mg/dL (albumin 3.4 gm/dL) although symptomati-
cally he had only mild fatigue. Creatinine level increase to
1.41 mg/dL compared to 0.86 mg/dL from the preceding
FIGURE 1. A) Lymph node (LN) biopsy (H&E x100). B) LN biopsy (H&E x400). C) LN biopsy (CD3). D) LN biopsy (CD4).
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month when calcium level was normal. Careful review of
the patient’s intake uncovered no consumption of exces-
sive calcium or exogenous vitamin D foods or supple-
ments. Additional testing revealed reduced parathyroid
hormone (PTH) of 3.6 pg/ml (reference range 18.5
−88 pg/ml) and parathyroid related protein (PTHrP)
24 pg/ml (reference range 14−27 pg/ml). The 25-hydrox-
yvitamin D3 (25[OH]D3, or calcidiol) level was low at
22.8 ng/ML (reference range 30.0−100.0 ng/mL). The
level of 1,25-dihydroxyvitamin D3 (1,25[OH]2D3, or calci-
triol) was significantly elevated at 136 pg/ml (reference
range 18−72pg/ml), with 1,25-dihydroxyvitamin D2 (1,25
[OH]2D2 < 8 pg/ml. Serum IF/SPEP revealed no mono-
clonal gammopathy. CT scan of chest/abdomen/pelvis
showed stable disease as compared to the November
2018 (post-chemotherapy) scan and with no osseous
involvement.
Initially the patient was treated with therapeutic
doses of calcitonin and zoledronic acid. Prednisone was
continued at moderate doses (mean dose 0.5 mg/kg/
day) as the patient remained minimally symptomatic.
Calcium levels were reasonably controlled with this
approach. Surprisingly, over the next four months we
saw not only a reduction in medium calcium levels to
<11 mg/dL but also a decline in the Vit D, 1,25 (OH)2 level
to 70 pg/ml (reference range 18−72 pg/ml). At that point,
calcitonin and zoledronic acid were discontinued and
only low dose prednisone continued.
He did well for a few months after resolution of hyper-
calcemia until onset of increasing fatigue and modest
increase in lymphadenopathy confirmed by scans. Vari-
ous treatment approaches were considered including
palliative targeted therapy including brentuximab, romi-
depsin, and belinostat. He opted then to proceed with
salvage chemotherapy in preparation of high-dose che-
motherapy followed by hematopoietic stem cell trans-
plant. He was treated with GDP (gemcitabine 1,000 mg/
m2 Day 1 and 8, dexamethasone 40 mg po Day 1, cis-
platin 75 mg/m2 Day 1) with intent to treat him every 3
weeks while awaiting stem cell collection. Treatment was
tolerated well and resulted in an approximate 50%
reduction in measurable lymphadenopathy. Loss of
insurance at that point delayed treatment and then the
patient elected to further delay re-institution of therapy
as he was symptomatically feeling good.
Four months from the time of last chemotherapy he
presented with discoloration (initially redness) of the right
index finger. There had been no precipitating trauma.
Pain was at first minimal and there was no associated
fever. No improvement occurred with outpatient oral or
parenteral antibiotics, with progression to frank ischemia
of the finger and new involvement of additional upper
and lower digits. Therefore, he was admitted. He
remained afebrile and vital signs were normal. He did not
look acutely ill. Admission complete blood count (CBC)
showed WBC of 8,800/uL with absolute neutrophil count
(ANC) of 5,400/uL, hemoglobin (Hgb) 10.6 gm/dL, and
platelet count 204,000/uL. Disseminated intravascular
coagulation (DIC) screen was negative and there had
been no exposure to heparins prior to onset of ischemia
(platelet factor IV antibody screen was nevertheless per-
formed, and negative). Blood and urine cultures were
negative for significant pathogens. Wound cultures,
gram stains, and fungal stains from the ischemic finger
revealed no organisms. Transthoracic and transesopha-
geal echocardiograms were both unrevealing. He was
treated empirically with vancomycin.
The ischemic changes in the finger progressed within
a few days of admission to irreversible necrosis necessi-
tating amputation of the distal portion of the right index
finger. Pathology revealed ischemic necrosis of skin and
soft tissue without evidence for osteomyelitis or organ-
isms (Figure 3A-C). There was an associated atypical
cellular infiltrate, compatible with involvement by AITL of
the small and medium-sized vessels, with recent and
organizing thrombosis and focal granulomatous vasculi-
tis. The infiltrating lymphocytes were predominantly CD5
positive, equivocal for CD3, and negative for CD20. This
granulomatous vasculitis process appeared to be limited
to involvement of blood vessels of the digits, with no
apparent involvement of sites commonly involved in
other vasculitides (renal, pulmonary, CNS).
ANA profile (antibodies to Sm (Smith), RNP, Scl-70,
JO-1, SS-B, dsDNA, ribosomal P protein, chromatin,
anti-centromeric antibodies) was negative except for
modest increase in SS-A/Ro antibody. Rheumatoid
FIGURE 2. A) Bone marrow at diagnosis (H&E X400). B) Bone marrow at diagnosis (CD3).
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factor (<10 IU/mL), anti-neutrophil antibodies (c-ANCA,
p-ANCA, atypical ANCA), cryoglobulins, and cold agglu-
tinins were not detected. Urine analysis and sediment
revealed no RBCs or casts. DIC screen, platelet factor IV
antibody screen, and antiphospholipid antibody/lupus
anticoagulant profile were negative. The patient was
treated with moderate dose methylprednisolone followed
by prednisone and aspirin 325 mg daily added. No fur-
ther ischemic events occurred, and he was eventually
discharged home. Discharge CBC showed normal neu-
trophil count, borderline thrombocytopenia, and hemo-
globin >9 gm/dL.
Approximately six weeks following the digit amputa-
tion, the patient presented to the outpatient clinic for
scheduled follow up with progressive pancytopenia
(WBC <700/uL, ANC <100/uL, and platelet count
<10,000/uL, hemoglobin 7.8 gm/dL, corrected reticulo-
cyte count <0.4%). Bone marrow exam showed hypo-
cellularity (10−15%) with no evidence of infiltrating
lymphoma by morphology. Immunohistochemical stains
revealed isolated clusters of CD3+ and CD5+, but no
CD20+ or CD30+ lymphocytes were identified. CD4+
T-cells showed reduced co-expression of CD7 in 50% of
cells by flow cytometry, and no expansion of CD8+ T-
cells. No cytogenetic abnormalities were noted. T-cell
gene rearrangement by polymerase chain reaction was
positive for both T-cell receptor beta and gamma chains.
No bacterial, fungal, or mycobacterial organisms were
identified by stain in the bone marrow. (Figure 4A, B)
Interestingly, the direct antiglobulin test was now
negative and haptoglobin was within normal range. He
no longer exhibited pan-hypergammaglobulinemia and
was now pan-hypogammaglobulinemia. Anti-neutrophil
antibody was not detected. Respiratory viral panel by
PCR (influenza A [H1, H1N1, H3], influenza B, coronavi-
rus [OC43, HKU1, 229E, NL63], human metapneumovir,
parainfluenza [1, 2, 3, 4], RSV, enterovirus/rhinovirus),
Hepatitis A, B, C screen, CMV DNA by PCR, HIV 1 and 2
antigen and antibodies, and mycobacterial stains and
cultures were negative. Human T- cell leukemia virus
(HTLV) 1 and 2 were considered but not tested, given the
patient had no clinical symptoms of HTLV associated
myelopathy. Furthermore, HTLV is not endemic to the
West Texas region.
CT scan of chest and abdomen surprisingly showed
no progressive adenopathy compared to his scans at
time of the digital ischemia.
The etiology of the severe AA was not clear. A careful
review of medication exposure revealed no probable
responsible agent. Management options were discussed
with the patient including immunosuppressive therapy
with cyclosporine, especially considering reported
responses of CSA in relapsed and refractory AITL. He
opted initially for supportive care and was managed as
an outpatient, receiving blood product support and pro-
phylactic anti-microbials. Two months later we repeated
a bone marrow at his request for reassessing his options.
This study again reconfirmed very severe AA with
FIGURE 3. A) Finger amputation; necrotizing vasculitis (H&E x200). B) Finger amputation; necrotizing vasculitis (H&E x400). C) Finger amputa-
tion; atypical lymphocytes (CD5£ 200).
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progressive hypo-cellularity (<10%). 500-cell differential
revealed 94% lymphocytes, 2 % monocytes, 1% ery-
throid precursors, 1% eosinophils/precursors, and 2 %
myeloid lineage (1% bands, 1% segmented neutrophils).
Stromal degenerative changes were now identified. This
specimen did reveal positive an 11.6% population of
atypical T lymphocytes co-expressing CD2, CD3, and
CD4, without co-expression evidence of CD7 by flow.
FISH for MDS/myeloid disorders revealed no abnormali-
ties and cytogenetics could not be done due to lack of
metaphases. Sequence analysis for specific gene muta-
tions were not performed.
Shortly after his second bone marrow, however, he
developed fever with unspecified sepsis resulting in an
extended stay at an outside facility. His performance
declined steadily after that point and he eventually died
at home on hospice care approximately five months after
onset of AA and eighteen months after diagnosis of AITL.
DISCUSSION
Angioimmunoblastic T-cell lymphoma is a peripheral
T-cell lymphoma with distinctive clinical as well as patho-
logical features. The median age at diagnosis is mid-60’s
with a male predilection.3 Over 80% of cases present in
advanced stage and over half with bone marrow involve-
ment and B symptoms. Elevated lactate dehydrogenase
(LDH), anemia, and hypergammaglobulinemia are pres-
ent at some point in most patients.4,5 The prognosis of
AITL is relatively poor with a reported 5-year median sur-
vival rate of 32%.7 A clear standard of treatment has still
not been uniformly established, and most patients will
experience short durations of remissions and incomplete
responses.
The precise pathogenesis of AITL remains specula-
tive, although the cell of origin of AITL has been shown
to be the follicular T helper (TFH) cell.
8 Deregulated T cell
receptor signaling via gene mutations appears key to the
pathogenesis of TFH derived neoplasms.
9 As the TFH
plays a key role in regulating B-cell activation, the subse-
quent loss of the normal B cell regulatory function of TFH
following malignant transformation, along with perhaps
other additional pathogenic changes such as the devel-
opment of Epstein-Barr viral (EBV) induced B cell immu-
noblasts, are likely contributing factors to the relatively
large number of patients with AITL presenting with auto-
immune related disease features. 10 In the present case,
EBV was noted in some CD20 positive B-lymphocytes of
the lymph nodes and bone marrow.
In large patient series, commonly reported immune
related features have included hypergammaglobuline-
mia (usually polyclonal), warm autoantibody hemolytic
anemia, and elevated non-specific inflammatory
markers (erythrocyte sedimentation rate, C-reactive
protein). 2,4−6 Immune thrombocytopenia, cold aggluti-
nins, polyarthritis, polychondritis, glomerulonephritis,
circulating immune complexes, and autoimmune anti-
body positivity (rheumatoid factor, smooth muscle,
anti-nuclear) are reported less frequently.
It was evident when reviewing the complications
noted in our patient that the incidence of hypercalcemia
(defined by a corrected serum calcium level of greater
than 10.5 mg/dL) in AITL appears to be less common
than in other lymphoma subtypes. Hypercalcemia was
not listed as a complication in most large series or
reviews that examined clinical and laboratory features in
AITL.3-6,11 Only 3 of 184 patients with AITL characterized
by the International Peripheral T-Cell Lymphoma Project
developed hypercalcemia.2 Furthermore, individual case
reports of hypercalcemia complicating AITL are few.
Consequently, there is a paucity of information regarding
the mechanism and management of hypercalcemia in
AITL. Traditionally, most cases of hypercalcemia in non-
Hodgkin’s lymphomas had been attributed to elevated
serum levels of either PTHrP or 1,25-dihydroxyvitamin
D3. Elevated 1,25-dihydroxyvitamin D3 is most often due
to increased extrarenal production via autonomous1-
a-hydroxylase activity from tumor cells, tissue macro-
phages, or both.12,13 Though the development of hyper-
calcemia in T cell malignancies is well postulated
through dysregulation of RANKL with increased
osteoclastic activity mediated by osteoclastic activating
factors (i.e. macrophage inflammatory protein-1a
(MIP-1a)), specifically in adult T cell leukemia.14,15 The
FIGURE 4. A) Bone marrow showing hypoplasia with lymphoid aggregate (AITL) (H&E x100). B) Bone marrow showing hypoplasia with scattered
atypical lymphocytes (CD5£ 200).
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pathophysiologic mechanism of hypercalcemia may be
similar in cases of AITL. However, recent reports have
indicated that in a significant number of non-Hodgkin
lymphoma patients, the mechanism will remain
unknown, or may be multifactorial.16,17
The few single case reports of hypercalcemia occur-
ring in AITL illustrate that this complication tended to
occur shortly after diagnosis of the disease yet contrib-
uted to poor outcome and shorten survival. Early cases
published before identification of PTHrP and the avail-
ability of vitamin D metabolite assays suggested ele-
vated intact PTH as the likely etiology.18-21 Furthermore,
in the case by Gan, hypercalcemia developed after trans-
formation to “immunoblastic sarcoma.” So, in this case,
it is more likely that the development of hypercalcemia
was due to secondary clonal B immunoblasts (typically
EBV infected) transforming to diffuse large B cell lym-
phoma.18,22 Chams reported a case of hypercalcemia
at presentation of AITL. This was the only other case in
our literature search that reported elevation of 1,25-dihy-
droxyvitamin D3 as the likely cause of elevated calcium
level.22
In our case, we detected no secondary clonal B cell
contributing to the onset of hypercalcemia. Exogenous
calcium and vitamin D were not contributing factors. In
contrast to the other case reports discussed, our patient
developed hypercalcemia not as a pre-terminal event nor
at presentation but rather a number of months following
diagnosis and after initiation of chemotherapy. As his
disease did not appear to be significantly progressing at
that point, it is more likely that the increased production
of 1,25-dihydroxyvitamin D3 at that point was due to
associated macrophage conversion rather than tumor
cell mediated conversion. Since progression of lym-
phoma cells per se did not appear to be directly driving
the hypercalcemic process at that time, we elected to
manage the hypercalcemia with calcium lowering agents
(calcitonin and zoledronic acid) and steroids rather
than immediate second line chemotherapy or targeted
therapies.
Dermatological manifestation are not uncommon in
patients with AITL and may present in a variety of patterns
including maculopapular rash, plaques, generalized eryth-
roderma, and purpura.4,23 Lachenal reported that a cuta-
neous eruption was present at diagnosis in 35 of 77
patients.4 Although most exhibited only a maculopapular
morbilliform rash, 8 patients presented with histological
evidence of vasculitis. A perivascular infiltrate of atypical
lymphocytes was present in 3 patients. Martel examined
skin biopsies from ten patients with AITL and skin lesions
and found that even though clinical suspicion of direct
lymphomatous involvement (suspicious plaque-like lesion)
was present in only two patients, infiltrating malignant T-
cells could be detected in seven patients by TCR gamma
gene rearrangement, despite only two of those patients
exhibiting circulating malignant T-cells in blood.24
Although cutaneous vasculitis is not unusual in AITL
cases of severe skin necrosis appear to be very
uncommon, and vasculitis leading to frank digital ische-
mia, as occurred in our patient, distinctly rare. Mohan
reported a case of a patient with newly diagnosed AITL
presenting with discoloration of the digits and subse-
quent impending gangrene.25 The patient was noted to
have positive pANCA by ELISA. Biopsy of the skin
lesions were not reported. The patient responded to
pulse methylprednisolone. Cassuto described a patient
with newly diagnosed AITL and painless necrosis of dig-
its leading to amputation of one finger.26 Pathology
revealed IgG and C’3 deposits in the intima of dermal
arterioles. There was no apparent tumor infiltration in the
tissue. The patient again responded to steroid therapy.
In our case, the presentation of digital ischemia
occurred one year after initial presentation at a time
when the disease was progressing. Pathology revealed
granulomatous vasculitis with associated tumor infiltra-
tion. Autoantibody screening was negative for ANCA and
cryoglobulins, and no other organ appeared to be
affected by vasculitis. As in those cases noted by Martel,
infiltrating lymphocytes seemed to play a pivotal patho-
genetic role in the development of the vascular lesions.23
In prior cases involving clinically significant vasculitis of
the skin, our patient seemed to respond to re-initiation
of high dose corticosteroids. In our patient, the addition
of aspirin may also have provided benefit as no further
ischemic events were experienced.
AA occurred as a late complication in our patient.
Cytopenia due to marrow infiltration and/or autoimmunity
are not infrequent in AITL.2,4,5,27 Myelosuppression can
occur as a result of chemotherapy due to suppression of
hematopoietic stem cells self-renewal,28 however, such
suppression is usually temporary. In this case report,
patient underwent chemotherapy with CHOEP and GDP
chemotherapy regimens. The patient tolerated chemo-
therapy well, with transient cytopenia likely due to che-
motherapy-related myelosuppression, from which he
recovered completely. The onset of bone marrow hypo-
plasia that occurred about 5-6 months after exposure to
GDP is unlikely to be related to his previous chemothera-
peutic treatment, and to our knowledge, has not been
reported in the medical literature. However, cell specific
hypoplasia, such as pure red cell aplasia, with or without
autoimmune cytopenia (immune thrombocytopenia and
autoimmune neutropenia not associated with marrow
hypoplasia) are uncommon.27,29−33 Furthermore, non-
treatment associated idiopathic AA would appear to be
distinctly rare not only in AITL, but in other lymphomas
as well. The Severe Aplastic Anaemia Working Party of
the European Society of Blood and Bone Marrow Trans-
plantation (EBMT) examined cases from 83 transplant
centers covering a period between 1983-2015 and found
only 21 cases of AA in patients with a concomitant diag-
nosis of non-Hodgkin lymphoma.34 Of these 21 cases,
19 were in patients with B cell malignancies, and two
were reported as unspecified lymphoma. No cases of AA
and AITL were noted. In addition, we found only one
case report of AA in a patient with AITL via MEDLINE
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search.33 In that case report, AA developed 20 months
after achieving a complete remission utilizing interferon-
alpha. The authors speculated that cytokine-induced
deficiency in CD14+ monocytes and altered CD4+/CD8+
T-cell levels may have contributed to onset of AA. Post-
mortem bone marrow showed evidence of erythropha-
gocytosis, so an associated viral infection could not be
entirely ruled out.
Retrospectively, the possibility of HTLV-1 contribut-
ing to the complications encountered in this case was
considered. Archived tissue was not amenable for test-
ing. This patient was not located in an endemic region
for HTLV-1. All blood products were screened for the
virus. There was no manifestation specific of acute
HTLV-1 infection (e.g., myelopathy/spastic paraparesis)
and no histological or radiographic evidence for HTLV-1
associated malignancy (including the absence of lytic
bone lesions). There have been some reports of ATLL
variants mimicking AITL.35,36 However, the histological
evidence in this case is clearly supportive of AITL (CD4+
follicular helper T-cells expressing CD10, PD-1 (CD279),
CXCL13, and bcl-6) rather than ATLL variant. Rare cases
of HTLV-1 inhibition of erythropoiesis/red cell aplasia
have been reported, but to our knowledge frank pan-
hypoplasia have not been reported.37,38
In the present case there did not appear to be any
associated cause to explain the onset of severe AA,
including medications, nutritional factors, or infection.
The degree of tumor infiltration was minimal. There was
no evidence for myelodysplasia, non-T cell acquired
clonal abnormalities, or hematopoietic phagocytosis.
Furthermore, the more commonly reported viral causes
of AA were not detected, although a less common virus
could not be completely ruled out. As in the case by
Schwarzmeier, reduced CD8+ T-cells were noted at the
time of AA development, yet the significance of this
observation is unclear.39
The management of this patient’s AA ultimately was
supportive, given his poor performance status and per-
sonal wishes. Following suboptimal response to CHOEP
and GDP (given with intent of eventual high-dose chemo-
therapy and hematopoietic stem cell transplant), various
palliative treatment options were considered including
pralatrexate, belinostat, romidepsin, and brentuximab.3
However, issues such as the patient’s distance from the
treatment center, cost issues, and quality of life preferen-
ces early in his treatment factored into his decisions not
to pursue alternate therapies, while later in his course,
performance status decline and sequential complica-
tions ultimately led to the decision of palliative care at
end-of-life. Unfortunately, we can only speculate on
whether he could have benefited from cyclosporine fol-
lowing the late development of idiopathic AA. Although
no longer considered a preferred treatment modality in
the setting of relapsed and refractory AITL, cyclosporine
has been shown to induce meaningful responses.40−42
These observations have included patients with signifi-
cantly impaired hematopoiesis.
This case illustrates the frequent complexity and
challenges in managing patients with AITL. The unique
interactions of the malignant T-cell and associated non-
malignant B immunoblasts produces a myriad of autoim-
mune and cellular complications not typically seen in
other lymphoid malignancies. It also further underscores
the need for better understanding of its pathophysiology
and the development of more effective treatment
strategies.
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